ChondroGene Limited has completed the acquisition of GeneNews Inc. The principal asset of GeneNews is proprietary technology, in which ChondroGene presently holds certain licensing rights, in osteoarthritis, rheumatoid arthritis and traumatic joint injury. This technology can be applied to pharmacogenomics and personalized medicine, and in the development of novel diagnostics and therapeutics across a range Read more about Chondrogene Acquires Genenews[…]
Serenex, Inc. announced the signing of a research agreement with Roche which involves the utilization of Serenex’ novel chemoproteomics technologies within Roche’s drug discovery program. The companies will jointly evaluate how Serenex’ technologies may impact the identification of the most appropriate compounds to advance through drug discovery and development Richard S. Kent, M.D., President and Read more about Roche And Serenex Sign Agreement[…]
EntreMed, Inc. has announced the execution of an agreement granting Oxford BioMedica plc exclusive worldwide rights to develop the localized delivery of two gene targets from EntreMed as a possible treatment for the loss of vision. Neil Campbell, EntreMed President and Chief Operating Officer, commented, “Given Oxford BioMedica’s gene therapy expertise, we are pleased that Read more about Licensing Deal For EntreMed And Oxford BioMedica[…]
Discovery Partners International, Inc. of San Diego, California and Kyorin Pharmaceutical Co., Ltd. of Tokyo, Japan announced further details surrounding the research collaboration to identify drug candidates for an allergy target. Under the agreement, Discovery Partners International, Inc. has responsibility for assay development and hit identification. Kyorin receives worldwide rights to manufacture and market any Read more about Discovery Partners International, Inc. And Kyorin Pharmaceutical Co., Inc. Sign Drug Discovery Agreement[…]
Genzyme Corporation and SangStat Medical Corporation have reached an agreement under which Genzyme will acquire SangStat in an all cash transaction valued at $22.50 per outstanding share, or approximately $600 million. Genzyme expects to complete the acquisition in early September. The transaction is expected to be dilutive to Genzyme’s GAAP earnings due to amortization through Read more about Genzyme To Acquire SangStat Medical Corporation[…]
Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers Read more about Meridian Agrees License Deal With Corixa[…]
Invitrogen Corp. has acquired product lines and technology rights from Genicon Sciences Corp., including Genicon’s proprietary tools and methods for ultra-sensitive signal generation and detection, for approximately $2 million. Genicon Sciences is a privately held company located in San Diego. “Invitrogen’s goal is to become the preeminent partner for organizations performing disease research and drug Read more about Invitrogen Agrees Deal With Genicon[…]
Schering AG, and Philogen S.r.l., have announced that Schering acquired exclusive worldwide development and marketing rights for an antibody-based therapeutic fusion protein from Philogen. It is expected to have the potential to treat solid tumors by triggering immunological mechanisms. Financial details were not disclosed. “We consider antibodies to have the potential for outstanding efficacy in Read more about Schering, Philogen Agree License Deal[…]
Ciphergen Biosystems, Inc. has announced that Toronto Medical Laboratories (TML) has acquired Ciphergen’s AutoBiomarker ProteinChip System, with an objective of pursuing targeted assay development projects aimed at identifying new protein biomarkers that can be converted into commercial diagnostic tests as part of the TML reference lab business strategy. Ciphergen has granted TML, in conjunction with Read more about Toronto Medical Has Acquired Ciphergen’s Autobiomarker Proteinchip System[…]
ARIAD Pharmaceuticals, Inc. has announced a non- exclusive worldwide license agreement with DiscoveRx Corporation that grants DiscoveRx the right to commercialize drug-discovery assay products covered by ARIAD’s pioneering NF-(kappa)B patents. DiscoveRx will pay ARIAD an upfront license fee and annual license fees, as well as royalties and milestones based on drug- discovery product sales. In Read more about ARIAD Licenses NF-(kappa)B Technology To DiscoveRx[…]